Likuiditas cepet tharimmune.com (THAR)

Tharimmune, Inc. (THAR) is developing innovative immunotherapy to combat skin pathologies and tumors, focusing on the elimination of inflammation and itching. This price chart, which serves as confirmation of the market valuation, demonstrates the asset's dynamics, where the indicator stands at 5.10. Tharimmune, Inc. (THAR) is also developing drugs against chronic itching associated with liver pathologies in a niche segment, relying on the outsourcing of clinical trials to third-party contractors to reduce costs.

For an investor assessing the issuer's solvency, this quick ratio reflects the company's ability to meet its obligations using liquid assets (cash and accounts receivable), excluding low-liquidity inventory. For Tharimmune, Inc., whose value is driven by costly nanobody research and patents, this metric is critical as it demonstrates the capital cushion required to fund clinical trials without the risk of a liquidity gap.